BofA analyst Jason Gerberry downgraded ProKidney (PROK) to Underperform from Neutral with a price target of $1, down from $3.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- Prokidney’s REACT Study: A Promising Step in Diabetes and Kidney Disease Treatment
- Prokidney’s REACT Study: A New Hope for Diabetic Kidney Disease
- ProKidney Approves Key Proposals at Annual Meeting
- ProKidney’s Prospects: Analyst Maintains $3 Price Target Amid Rilparencel Developments and Financial Stability
- ProKidney Corp. Reports Increased Losses Amid Ongoing R&D